Vera Therapeutics, Inc. (VERA) stock
VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
$28.10−0.94 (-3.24%)
Close on Nov 13, 2026Market cap $2.02BP/E –Yield –
Vera Therapeutics cash
Cash and short-term investments held at the end of each period.
Vera Therapeutics's cash was $384.04M at Sep 30, 2026. For fiscal 2025 it was $714.59M, up 11.5% from the year before. The highest annual figure on record is $714.59M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $714.59M | +11.5% |
| FY2024 | Dec 31, 2024 | $640.85M | +298.7% |
| FY2023 | Dec 31, 2023 | $160.72M | +39.8% |
| FY2022 | Dec 31, 2022 | $114.95M | +43.7% |
| FY2021 | Dec 31, 2021 | $79.97M | +48.1% |
| FY2020 | Dec 31, 2020 | $54.00M | +1417.6% |
| FY2019 | Dec 31, 2019 | $3.56M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $384.04M | -22.8% |
| Q2 FY2026 | Jun 30, 2026 | $499.16M | -10.4% |
| Q1 FY2026 | Mar 31, 2026 | $596.76M | +1.2% |
| Q4 FY2025 | Dec 31, 2025 | $714.59M | +11.5% |
| Q3 FY2025 | Sep 30, 2025 | $497.39M | +40.8% |
| Q2 FY2025 | Jun 30, 2025 | $556.83M | +44.9% |
| Q1 FY2025 | Mar 31, 2025 | $589.83M | +46.1% |
| Q4 FY2024 | Dec 31, 2024 | $640.85M | +298.7% |
| Q3 FY2024 | Sep 30, 2024 | $353.31M | +120.9% |
| Q2 FY2024 | Jun 30, 2024 | $384.39M | +112.3% |
| Q1 FY2024 | Mar 31, 2024 | $403.66M | +104.4% |
| Q4 FY2023 | Dec 31, 2023 | $160.72M | +39.8% |
| Q3 FY2023 | Sep 30, 2023 | $159.94M | +39.4% |
| Q2 FY2023 | Jun 30, 2023 | $181.02M | +36.9% |
| Q1 FY2023 | Mar 31, 2023 | $197.45M | +30.6% |
| Q4 FY2022 | Dec 31, 2022 | $114.95M | +43.7% |
| Q3 FY2022 | Sep 30, 2022 | $114.71M | +32.6% |
| Q2 FY2022 | Jun 30, 2022 | $132.22M | +43.8% |
| Q1 FY2022 | Mar 31, 2022 | $151.23M | +203.4% |
| Q4 FY2021 | Dec 31, 2021 | $79.97M | +48.1% |
| Q3 FY2021 | Sep 30, 2021 | $86.48M | +5586.0% |
| Q2 FY2021 | Jun 30, 2021 | $91.97M | +2164.1% |
| Q1 FY2021 | Mar 31, 2021 | $49.85M | +708.2% |
| Q4 FY2020 | Dec 31, 2020 | $54.00M | +1417.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.52M | – |
| Q2 FY2020 | Jun 30, 2020 | $4.06M | – |
| Q1 FY2020 | Mar 31, 2020 | $6.17M | – |
| Q4 FY2019 | Dec 31, 2019 | $3.56M | – |
See a number that looks wrong?